Journal article 603 views 137 downloads
‘New/Designer Benzodiazepines’: An Analysis of the Literature and Psychonauts’ Trip Reports
Laura Orsolini,
John M. Corkery,
Stefania Chiappini,
Amira Guirguis 
,
Alessandro Vento,
Domenico De Berardis,
Duccio Papanti,
Fabrizio Schifano
,
Alessandro Vento,
Domenico De Berardis,
Duccio Papanti,
Fabrizio Schifano
Current Neuropharmacology, Volume: 18, Issue: 9, Pages: 809 - 837
Swansea University Author:
Amira Guirguis
-
PDF | Accepted Manuscript
Download (1.49MB)
DOI (Published version): 10.2174/1570159x18666200110121333
Abstract
BACKGROUND:NPS belonging to the benzodiazepine (BZD) class, e.g., 'legal/designer BZDs'/'research chemicals', have recently emerged on the drug (mainly online/virtual) market.OBJECTIVE:Whilst certain NPS belonging to the BZD class possess pharmacological profiles similar to contr...
| Published in: | Current Neuropharmacology |
|---|---|
| ISSN: | 1570-159X |
| Published: |
Bentham Science Publishers Ltd.
2020
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa53322 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract: |
BACKGROUND:NPS belonging to the benzodiazepine (BZD) class, e.g., 'legal/designer BZDs'/'research chemicals', have recently emerged on the drug (mainly online/virtual) market.OBJECTIVE:Whilst certain NPS belonging to the BZD class possess pharmacological profiles similar to controlled pharmaceutical BZDs, clinical and pharmacological profiles of current emerging BZDs are still not well-described. Therefore, there is a need to increase clinicians'/public health knowledge/awareness, to incentive harm reduction strategies.METHOD:A comprehensive overview was carried out by using the EMCDDA/EDND database regularly monitored by our research team, by specifically looking at the 'new BZDs' so far notified. Furthermore, given the limitation of peer-reviewed data published so far, a nonparticipant multilingual qualitative netnographic study was conducted to obtain further clinical/pharmacological/toxicological data, including psychonauts' online trip reports.RESULTS:First designer BZDs appeared as NPS around 2007. So far, 29 designer BZDs have been notified to the EMCDDA, being some of them extremely powerful, also at lower dosages. They are sold as tablets/powder/pellets/capsules/blotters/liquids, at very affordable prices, and variably administered. Some are also sold on the illicit drugmarket as counterfeit forms of traditional BZDs or as either adulterants or diluents in heroin or other synthetic opioids/cannabinoids. Nowadays, there is no guarantee of the quality of designer BZDs composition/purification and, hence, most NPS consumers may be inadvertently exposed to unsafe and harmful compounds.CONCLUSIONS:Given the limited information on their pharmacology/toxicity, variations in dosage, onset of effects, combination of substances, potency, and general patient or individual variability, the concomitant use of these substances with other drugs entails several and unpredictable risks. |
|---|---|
| Keywords: |
New benzodiazepines, NPS, Novel psychoactive substances, Benzodiazepines, Designer benzodiazepines, Synthetic benzodiazepines |
| College: |
Faculty of Medicine, Health and Life Sciences |
| Issue: |
9 |
| Start Page: |
809 |
| End Page: |
837 |